1-19 of 19
Martine Piccart
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, Chiara Gargiuli, Loris De Cecco, Evandro de Azambuja, Debora Fumagalli, Christos Sotiriou, Nadia Harbeck, Miguel Izquierdo, Paolo Nuciforo, Jens Huober, Vera Cappelletti, Saverio Cinieri, Martine Piccart, Maria Grazia Daidone, Giancarlo Pruneri, Mario Paolo Colombo, Elda Tagliabue, Paolo Verderio, Serena Di Cosimo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6307–6313.
https://doi.org/10.1158/1078-0432.CCR-21-1600
Published: 01 December 2021
View article titled, Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Open the PDF for Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis in another window
Includes: Supplementary data
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen R.D. Johnston, Stephen K. Chia
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5172–5177.
https://doi.org/10.1158/1078-0432.CCR-20-0224
Published: 01 October 2020
View article titled, <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Open the PDF for <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials in another window
Includes: Supplementary data
Journal Articles

What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?

Mariana Brandão, Rafael Caparica, Luca Malorni, Aleix Prat, Lisa A. Carey, Martine Piccart
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2783–2788.
https://doi.org/10.1158/1078-0432.CCR-19-2612
Published: 15 June 2020
View article titled, What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?
Open the PDF for What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer? in another window
Journal Articles

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial

Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Paola Tiberio, Marilena V. Iorio, Florentine Hilbers, Evandro de Azambuja, Lorena de la Peña, Miguel Izquierdo, Jens Huober, José Baselga, Martine Piccart, Filippo G. de Braud, Giovanni Apolone, Paolo Verderio, Maria Grazia Daidone
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (13): 3887–3895.
https://doi.org/10.1158/1078-0432.CCR-18-2507
Published: 01 July 2019
View article titled, Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Open the PDF for Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Françoise Rothé, Maria Joao Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, Jose Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah-Jane Dawson, Michail Ignatiadis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3581–3588.
https://doi.org/10.1158/1078-0432.CCR-18-2521
Published: 14 June 2019
View article titled, Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Open the PDF for Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1434.
https://doi.org/10.1158/1078-0432.CCR-18-4267
Published: 15 February 2019
View article titled, Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Journal Articles

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers

Elisabetta Marangoni, Cécile Laurent, Florence Coussy, Rania El-Botty, Sophie Château-Joubert, Jean-Luc Servely, Ludmilla de Plater, Franck Assayag, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Justine Fleury, Sophie Vacher, David Gentien, Audrey Rapinat, Pierre Foidart, Nor Eddine Sounni, Agnès Noel, Anne Vincent-Salomon, Marick Lae, Didier Decaudin, Sergio Roman-Roman, Ivan Bièche, Martine Piccart, Fabien Reyal
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2605–2615.
https://doi.org/10.1158/1078-0432.CCR-17-3490
Published: 31 May 2018
View article titled, Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
Open the PDF for Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers in another window
Includes: Supplementary data
Journal Articles

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4323–4334.
https://doi.org/10.1158/1078-0432.CCR-16-2287
Published: 01 August 2017
View article titled, HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Includes: Supplementary data
Journal Articles

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data

Ivana Bozovic-Spasojevic, Dimitrios Zardavas, Sylvain Brohée, Lieveke Ameye, Debora Fumagalli, Felipe Ades, Evandro de Azambuja, Yacine Bareche, Martine Piccart, Marianne Paesmans, Christos Sotiriou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (11): 2702–2712.
https://doi.org/10.1158/1078-0432.CCR-16-0979
Published: 31 May 2017
View article titled, The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Open the PDF for The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data in another window
Includes: Supplementary data
Journal Articles

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tarh, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluis Parra, Ludmila Prudkin, José Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidtmann, Joaquin Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart, José Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 569–576.
https://doi.org/10.1158/1078-0432.CCR-14-1824
Published: 01 February 2015
View article titled, High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Open the PDF for High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab in another window
Includes: Supplementary data
Journal Articles

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors

Amir Sonnenblick, Debora Fumagalli, Hatem A. Azim, Jr, Christos Sotiriou, Martine Piccart
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6242–6246.
https://doi.org/10.1158/1078-0432.CCR-14-1086
Published: 14 December 2014
View article titled, New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T<sub>1a,b</sub>N<sub>0</sub>M<sub>0</sub> Tumors
Open the PDF for New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T<sub>1a,b</sub>N<sub>0</sub>M<sub>0</sub> Tumors in another window
Journal Articles

When will Molecular Fingerprints Dominate Cancer Treatment Selection?

Martine Piccart-Gebhart, Phuong Dinh, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22_Supplement): CN05-03.
Published: 15 August 2014
View article titled, When will Molecular Fingerprints Dominate Cancer Treatment Selection?
Journal Articles

Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment

Christine Desmedt, Samira Majjaj, Naima Kheddoumi, Sandeep K. Singhal, Benjamin Haibe-Kains, Frank El Ouriaghli, Carole Chaboteaux, Stefan Michiels, Françoise Lallemand, Fabrice Journe, Hughes Duvillier, Sherene Loi, John Quackenbush, Sophie Dekoninck, Cédric Blanpain, Laurence Lagneaux, Nawal Houhou, Mauro Delorenzi, Denis Larsimont, Martine Piccart, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1004–1014.
https://doi.org/10.1158/1078-0432.CCR-11-0383
Published: 14 February 2012
View article titled, Characterization and Clinical Evaluation of CD10<sup>+</sup> Stroma Cells in the Breast Cancer Microenvironment
Open the PDF for Characterization and Clinical Evaluation of CD10<sup>+</sup> Stroma Cells in the Breast Cancer Microenvironment in another window
Includes: Supplementary data
Journal Articles

HER-2 as a Target for Breast Cancer Therapy

Michail Ignatiadis, Christine Desmedt, Christos Sotiriou, Evandro de Azambuja, Martine Piccart
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 1848–1852.
https://doi.org/10.1158/1078-0432.CCR-08-1844
Published: 16 March 2009
View article titled, HER-2 as a Target for Breast Cancer Therapy
Open the PDF for HER-2 as a Target for Breast Cancer Therapy in another window
Journal Articles

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

Christine Desmedt, Benjamin Haibe-Kains, Pratyaksha Wirapati, Marc Buyse, Denis Larsimont, Gianluca Bontempi, Mauro Delorenzi, Martine Piccart, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5158–5165.
https://doi.org/10.1158/1078-0432.CCR-07-4756
Published: 12 August 2008
View article titled, Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Open the PDF for Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 144–151.
https://doi.org/10.1158/1078-0432.CCR-05-1571
Published: 05 January 2006
View article titled, Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer
Open the PDF for Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer in another window
Journal Articles

Influence of Amifostine on the Toxicity and Pharmacokinetics of Docetaxel in Metastatic Breast Cancer Patients: A Pilot Study

Gilles Freyer, Philippe Hennebert, Ahmad Awada, Thierry Gil, Joseph Kerger, Jean Selleslags, Christiane Brassinne, Martine Piccart, Dominique de Valeriola
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (1): 95–102.
Published: 01 January 2002
View article titled, Influence of Amifostine on the Toxicity and Pharmacokinetics of Docetaxel in Metastatic Breast Cancer Patients: <subtitle>A Pilot Study</subtitle>
Open the PDF for Influence of Amifostine on the Toxicity and Pharmacokinetics of Docetaxel in Metastatic Breast Cancer Patients: <subtitle>A Pilot Study</subtitle> in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors

Eric Van Den Neste, Dominique de Valeriola, Joseph Kerger, Harry Bleiberg, Zlatko Kusenda, Christiane Brassinne, Sylvie Bartholomeus, Jean Selleslags, Philippe Hennebert, Hilda Wythouck, Isabelle Cazenave, Florence Lefresne-Soulas, Martine Piccart
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 64–71.
Published: 01 January 2000
View article titled, A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors
Open the PDF for A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors in another window